|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
|
CA2603408C
(en)
|
2005-03-31 |
2018-08-21 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
|
US8940871B2
(en)
|
2006-03-20 |
2015-01-27 |
The Regents Of The University Of California |
Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting
|
|
ES2654040T3
(es)
|
2006-03-31 |
2018-02-12 |
Chugai Seiyaku Kabushiki Kaisha |
Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos
|
|
CA2647846C
(en)
|
2006-03-31 |
2016-06-21 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
|
JP6126773B2
(ja)
|
2007-09-04 |
2017-05-10 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
癌のターゲッティングおよび検出のための高親和性抗前立腺幹細胞抗原（ｐｓｃａ）抗体
|
|
MX336725B
(es)
|
2007-09-26 |
2016-01-28 |
Chugai Pharmaceutical Co Ltd |
Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
|
|
RU2526512C2
(ru)
|
2007-09-26 |
2014-08-20 |
Чугаи Сейяку Кабусики Кайся |
Модифицированная константная область антитела
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
EP2313109A2
(en)
|
2008-07-02 |
2011-04-27 |
Emergent Product Development Seattle, LLC |
Il6 immunotherapeutics
|
|
KR20170091801A
(ko)
|
2008-10-02 |
2017-08-09 |
압테보 리서치 앤드 디벨롭먼트 엘엘씨 |
Ｃｄ86 길항제 다중-표적 결합 단백질
|
|
EP3495000A1
(en)
|
2009-02-17 |
2019-06-12 |
Cornell Research Foundation, Inc. |
Methods and kits for diagnosis of cancer and prediction of therapeutic value
|
|
US20120071634A1
(en)
|
2009-03-19 |
2012-03-22 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody Constant Region Variant
|
|
US9228017B2
(en)
|
2009-03-19 |
2016-01-05 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
|
US20100256340A1
(en)
|
2009-04-07 |
2010-10-07 |
Ulrich Brinkmann |
Trivalent, bispecific antibodies
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
WO2011034605A2
(en)
|
2009-09-16 |
2011-03-24 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
|
US10150808B2
(en)
|
2009-09-24 |
2018-12-11 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant regions
|
|
MX337600B
(es)
|
2009-12-02 |
2016-03-11 |
Imaginab Inc |
Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antigeno de membrana especifico para prostata de humano (psma) y metodos para su uso.
|
|
JP5889181B2
(ja)
*
|
2010-03-04 |
2016-03-22 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
SI2544719T1
(sl)
|
2010-03-12 |
2019-11-29 |
Debiopharm Int Sa |
CD37-povezovalne molekule in njihovi imunokonjugati
|
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
|
JP2013533746A
(ja)
|
2010-07-06 |
2013-08-29 |
アベオ ファーマシューティカルズ， インコーポレイテッド |
抗ｒｏｎ抗体
|
|
CN105585630B
(zh)
|
2010-07-29 |
2020-09-15 |
Xencor公司 |
具有修改的等电点的抗体
|
|
CA3017869C
(en)
|
2010-11-10 |
2021-07-27 |
Genentech, Inc. |
Pyrazole aminopyrimidine derivatives as lrrk2 modulators
|
|
EP2646470B1
(en)
|
2010-11-30 |
2017-03-01 |
F. Hoffmann-La Roche AG |
Low affinity anti-transferrin receptor antibodies and their use to transfer therapeutic scfv across the blood brain barrier
|
|
BR112013019975A2
(pt)
|
2011-02-28 |
2017-08-01 |
Hoffmann La Roche |
proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
|
|
RU2013141078A
(ru)
|
2011-02-28 |
2015-04-10 |
Ф. Хоффманн-Ля Рош Аг |
Одновалентные антигенсвязывающие белки
|
|
JP6018622B2
(ja)
|
2011-04-01 |
2016-11-02 |
イミュノジェン， インコーポレイテッド |
Ｃｄ３７結合性分子及びその免疫複合体
|
|
US20140161800A1
(en)
|
2011-04-22 |
2014-06-12 |
John W. Blankenship |
Prostate-Specific Membrane Antigen Binding Proteins and Related Compositions and Methods
|
|
US9738707B2
(en)
*
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
|
ES2723181T3
(es)
|
2011-07-29 |
2019-08-22 |
Univ Pennsylvania |
Receptores de conmutación coestimulante
|
|
KR101870555B1
(ko)
|
2011-08-23 |
2018-06-22 |
로슈 글리카트 아게 |
T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US20130273089A1
(en)
|
2011-11-03 |
2013-10-17 |
Tolera Therapeutics, Inc. |
Antibody and methods for selective inhibition of t-cell responses
|
|
KR20140091038A
(ko)
|
2011-11-03 |
2014-07-18 |
톨러러 세러퓨틱스 인코포레이티드 |
T-세포 반응의 선택적 억제를 위한 항체 및 방법
|
|
BR112014012005A2
(pt)
|
2011-11-21 |
2017-12-19 |
Genentech Inc |
composições, métodos, formulação farmacêutica e artigo
|
|
CN104011221B
(zh)
|
2011-12-20 |
2019-01-08 |
米迪缪尼有限公司 |
用于双特异性抗体支架的经修饰的多肽
|
|
EP2836512B1
(en)
|
2012-04-11 |
2018-10-24 |
F.Hoffmann-La Roche Ag |
Improved antibody light chains
|
|
CN104487587A
(zh)
*
|
2012-04-20 |
2015-04-01 |
新兴产品开发西雅图有限公司 |
Cd3结合多肽
|
|
DK2847231T3
(da)
|
2012-05-10 |
2019-10-14 |
Bioatla Llc |
Multispecifikke monoklonale antistoffer
|
|
RU2670491C2
(ru)
*
|
2012-07-05 |
2018-10-23 |
Дженентек, Инк. |
Система экспрессии и секреции
|
|
BR112015000798A2
(pt)
*
|
2012-07-13 |
2017-06-27 |
Zymeworks Inc |
heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3
|
|
JOP20200236A1
(ar)
*
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
EP2905290B1
(en)
|
2012-10-05 |
2019-12-04 |
Kyowa Kirin Co., Ltd. |
Heterodimeric protein composition
|
|
KR20150064068A
(ko)
|
2012-10-08 |
2015-06-10 |
로슈 글리카트 아게 |
2개의 Fab 단편을 포함하는 FC-부재 항체 및 이용 방법
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
KR102391731B1
(ko)
|
2013-01-14 |
2022-04-27 |
젠코어 인코포레이티드 |
신규한 이형이량체 단백질
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP2945969A1
(en)
|
2013-01-15 |
2015-11-25 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
CA2900764A1
(en)
*
|
2013-02-08 |
2014-08-14 |
Stemcentrx, Inc. |
Novel multispecific constructs
|
|
KR102332790B1
(ko)
|
2013-02-15 |
2021-12-01 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
키메라 항원 수용체 및 이의 이용 방법
|
|
CA2896370A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
KR20180023035A
(ko)
|
2013-02-26 |
2018-03-06 |
로슈 글리카트 아게 |
이중특이적 t 세포 활성화 항원 결합 분자
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
DK2970486T3
(en)
|
2013-03-15 |
2018-08-06 |
Xencor Inc |
MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
|
|
KR102266819B1
(ko)
|
2013-04-29 |
2021-06-18 |
에프. 호프만-라 로슈 아게 |
Fc-수용체 결합 개질된 비대칭 항체 및 이의 사용 방법
|
|
SG10201800492PA
(en)
|
2013-04-29 |
2018-03-28 |
Hoffmann La Roche |
Human fcrn-binding modified antibodies and methods of use
|
|
CN105164158A
(zh)
|
2013-04-29 |
2015-12-16 |
豪夫迈·罗氏有限公司 |
消除对FcRn-结合的抗-IGF-1R抗体及其在血管性眼病治疗中的用途
|
|
CN105339389B
(zh)
|
2013-05-02 |
2021-04-27 |
安奈普泰斯生物有限公司 |
针对程序性死亡-1(pd-1)的抗体
|
|
US10087248B2
(en)
|
2013-05-22 |
2018-10-02 |
Metabolic Engineering Laboratories Co., Ltd. |
Anti-TNF-α/CXCL10 double-targeting antibody and use thereof
|
|
EP3019622A4
(en)
*
|
2013-07-12 |
2017-06-14 |
Zymeworks Inc. |
Bispecific cd3 and cd19 antigen binding contructs
|
|
WO2015046467A1
(ja)
|
2013-09-27 |
2015-04-02 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
|
CA2922912A1
(en)
|
2013-10-11 |
2015-04-16 |
F. Hoffmann-La Roche Ag |
Multispecific domain exchanged common variable light chain antibodies
|
|
WO2015066413A1
(en)
|
2013-11-01 |
2015-05-07 |
Novartis Ag |
Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
|
|
AU2014348657A1
(en)
|
2013-11-13 |
2016-05-19 |
Novartis Ag |
mTOR inhibitors for enhancing the immune response
|
|
JP6449295B2
(ja)
*
|
2013-12-17 |
2019-01-09 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ３抗体および使用方法
|
|
SG11201604815RA
(en)
|
2013-12-19 |
2016-07-28 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
EA201600473A1
(ru)
|
2013-12-20 |
2016-12-30 |
Ф. Хоффманн-Ля Рош Аг |
ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ
|
|
KR20160104628A
(ko)
|
2014-01-03 |
2016-09-05 |
에프. 호프만-라 로슈 아게 |
이중특이성 항-합텐/항-혈액뇌장벽 수용체 항체, 그의 복합체 및 혈액뇌장벽 셔틀로서 그의 용도
|
|
CN111057147B
(zh)
|
2014-01-06 |
2023-11-10 |
豪夫迈·罗氏有限公司 |
单价血脑屏障穿梭模块
|
|
WO2015109131A2
(en)
*
|
2014-01-15 |
2015-07-23 |
Zymeworks Inc. |
Bi-specific cd3 and cd19 antigen-binding constructs
|
|
RU2727639C2
(ru)
|
2014-01-15 |
2020-07-22 |
Ф.Хоффманн-Ля Рош Аг |
Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
|
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
CN106103488B
(zh)
*
|
2014-02-10 |
2021-07-30 |
默克专利有限公司 |
靶向TGFβ抑制
|
|
PH12020550202B1
(en)
*
|
2014-03-05 |
2023-11-15 |
Autolus Ltd |
Chimeric antigen receptor (car) with antigen binding domains to the t cell receptor beta constant region
|
|
US11385233B2
(en)
|
2015-03-05 |
2022-07-12 |
Autolus Limited |
Methods of depleting malignant T-cells
|
|
US11982673B2
(en)
|
2014-03-05 |
2024-05-14 |
Autolus Limited |
Methods
|
|
WO2015138925A1
(en)
*
|
2014-03-14 |
2015-09-17 |
University Of Utah Research Foundation |
Ron inhibitors for use in preventing and treating bone loss
|
|
EP3116909B1
(en)
|
2014-03-14 |
2019-11-13 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
CN106163547A
(zh)
|
2014-03-15 |
2016-11-23 |
诺华股份有限公司 |
使用嵌合抗原受体治疗癌症
|
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
SMT201900218T1
(it)
|
2014-03-24 |
2019-05-10 |
Novartis Ag |
Composti organici di monobattami, per il trattamento di infezioni batteriche
|
|
TN2017000532A1
(en)
|
2014-03-28 |
2019-04-12 |
Xencor Inc |
Bispecific antibodies that bind to cd38 and cd3.
|
|
CN113092788A
(zh)
|
2014-04-02 |
2021-07-09 |
豪夫迈·罗氏有限公司 |
检测多特异性抗体轻链错配的方法
|
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
|
RU2021134101A
(ru)
|
2014-04-03 |
2022-03-22 |
АйДжиЭм БАЙОСАЙЕНСИЗ, ИНК. |
Модифицированная j-цепь
|
|
LT3129470T
(lt)
|
2014-04-07 |
2021-07-12 |
Novartis Ag |
Vėžio gydymas naudojant anti-cd19 chimerinį antigeno receptorių
|
|
RU2577226C2
(ru)
*
|
2014-04-10 |
2016-03-10 |
Общество с ограниченной ответственностью, "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") |
Способ получения биспецифических антител против cd3*cd19 формата флексибоди в клетках млекопитающих
|
|
KR102460736B1
(ko)
*
|
2014-05-10 |
2022-10-31 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
화학적으로-로킹된 이중특이적 항체
|
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
|
RU2705299C2
(ru)
|
2014-06-26 |
2019-11-06 |
Ф. Хоффманн-Ля Рош Аг |
Антитела против 5-бром-2'-дезоксиуридина и способы применения
|
|
US20170218091A1
(en)
*
|
2014-07-03 |
2017-08-03 |
Abbvie Inc. |
Monovalent binding proteins
|
|
CN107109419B
(zh)
|
2014-07-21 |
2020-12-22 |
诺华股份有限公司 |
使用cd33嵌合抗原受体治疗癌症
|
|
BR112017001183A2
(pt)
|
2014-07-21 |
2017-11-28 |
Novartis Ag |
tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
|
|
WO2016014530A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
EP4205749A1
(en)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
JP6464255B2
(ja)
|
2014-08-04 |
2019-02-06 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性ｔ細胞活性化抗原結合分子
|
|
US10160726B2
(en)
|
2014-08-06 |
2018-12-25 |
Novartis Ag |
Quinolone derivatives as antibacterials
|
|
CA2958200A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
|
|
ES2791248T3
(es)
|
2014-08-19 |
2020-11-03 |
Novartis Ag |
Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
|
|
CA2959045A1
(en)
|
2014-09-12 |
2016-03-17 |
The University Of Washington |
Wnt signaling agonist molecules
|
|
AU2015314744A1
(en)
|
2014-09-12 |
2017-03-02 |
Genentech, Inc. |
Anti-CLL-1 antibodies and immunoconjugates
|
|
AU2015314756A1
(en)
|
2014-09-13 |
2017-03-16 |
Novartis Ag |
Combination therapies of alk inhibitors
|
|
EA201790624A1
(ru)
|
2014-09-17 |
2017-08-31 |
Новартис Аг |
Нацеливание цитотоксических клеток с химерными рецепторами для адоптивной иммунотерапии
|
|
EP3662903A3
(en)
|
2014-10-03 |
2020-10-14 |
Novartis AG |
Combination therapies
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
AU2015330898B2
(en)
|
2014-10-08 |
2022-03-10 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
|
SG11201702805TA
(en)
*
|
2014-10-08 |
2017-05-30 |
Hoffmann La Roche |
Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents
|
|
US11952421B2
(en)
|
2014-10-09 |
2024-04-09 |
Bristol-Myers Squibb Company |
Bispecific antibodies against CD3EPSILON and ROR1
|
|
CN114920840A
(zh)
|
2014-10-14 |
2022-08-19 |
诺华股份有限公司 |
针对pd-l1的抗体分子及其用途
|
|
WO2016065245A1
(en)
|
2014-10-24 |
2016-04-28 |
Incept, Llc |
Extra luminal scaffold
|
|
US10316094B2
(en)
|
2014-10-24 |
2019-06-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistance
|
|
KR20170078677A
(ko)
|
2014-11-06 |
2017-07-07 |
에프. 호프만-라 로슈 아게 |
Fcrn-결합이 개질된 fc-영역 변이체 및 이의 사용 방법
|
|
JP6576456B2
(ja)
|
2014-11-06 |
2019-09-18 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
修飾されたＦｃＲｎ結合特性およびプロテインＡ結合特性を有するＦｃ領域変種
|
|
AU2015350075B2
(en)
|
2014-11-17 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Methods for tumor treatment using CD3xCD20 bispecific antibody
|
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
EP3221355B1
(en)
|
2014-11-20 |
2020-10-07 |
F.Hoffmann-La Roche Ag |
Combination therapy of t cell activating bispecific antigen binding molecules cd3 and folate receptor 1 (folr1) and pd-1 axis binding antagonists
|
|
DK3221357T3
(da)
|
2014-11-20 |
2020-08-10 |
Hoffmann La Roche |
Fælles letkæder og fremgangsmåder til anvendelse
|
|
EA201791121A1
(ru)
|
2014-11-20 |
2018-04-30 |
Ф. Хоффманн-Ля Рош Аг |
Активирующие т-клетки биспецифические антигенсвязывающие молекулы против folri и cd3
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
BR112017011092A2
(pt)
|
2014-11-26 |
2017-12-26 |
Xencor Inc |
anticorpos heterodiméricos que ligam cd3 e antígenos de tumor
|
|
CN107406512A
(zh)
|
2014-11-26 |
2017-11-28 |
Xencor公司 |
结合cd3和cd38的异二聚体抗体
|
|
CN107001482B
(zh)
|
2014-12-03 |
2021-06-15 |
豪夫迈·罗氏有限公司 |
多特异性抗体
|
|
WO2016090034A2
(en)
|
2014-12-03 |
2016-06-09 |
Novartis Ag |
Methods for b cell preconditioning in car therapy
|
|
CR20170260A
(es)
|
2014-12-16 |
2017-08-21 |
Novartis Ag |
COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC
|
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
|
ES2824151T3
(es)
|
2014-12-19 |
2021-05-11 |
Alkermes Inc |
Proteínas de fusión Fc monocatenarias
|
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
AU2015374296B2
(en)
|
2014-12-29 |
2021-09-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
KR102663073B1
(ko)
|
2015-01-08 |
2024-05-07 |
젠맵 에이/에스 |
Cd3 및 cd20에 대항한 이중특이적 항체
|
|
IL308212A
(en)
|
2015-01-20 |
2024-01-01 |
Igm Biosciences Inc |
Tumor necrosis factor-α receptor binding molecules and their uses
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
CN107207622B
(zh)
*
|
2015-02-04 |
2021-09-28 |
苏黎世大学 |
Hla-b27同二聚体用于癌症治疗的用途
|
|
HUE054642T2
(hu)
|
2015-03-04 |
2021-09-28 |
Igm Biosciences Inc |
CD20 kötõ molekulák és ezek felhasználása
|
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
|
MY178919A
(en)
|
2015-03-09 |
2020-10-23 |
Agensys Inc |
Antibody drug conjugates (adc) that bind to flt3 proteins
|
|
JP6692826B2
(ja)
|
2015-03-10 |
2020-05-13 |
アドゥロ バイオテック，インク． |
「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
|
|
US10744157B2
(en)
|
2015-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
Anti-MICA antigen binding fragments, fusion molecules, cells which express and methods of using
|
|
EP3404411A3
(en)
*
|
2015-03-31 |
2019-02-13 |
Fundamental Solutions Corporation |
Biosensor system for the rapid detection of analytes
|
|
US9752199B2
(en)
|
2015-03-31 |
2017-09-05 |
Fundamental Solutions Corporation |
Biosensor system for the rapid detection of analytes
|
|
US11142587B2
(en)
|
2015-04-01 |
2021-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide hetero-oligomer
|
|
ES2876974T3
(es)
|
2015-04-07 |
2021-11-15 |
Novartis Ag |
Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
|
|
SG11201708191XA
(en)
|
2015-04-08 |
2017-11-29 |
Novartis Ag |
Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
|
|
EP4234685A3
(en)
|
2015-04-17 |
2023-09-06 |
Novartis AG |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
US12128069B2
(en)
|
2015-04-23 |
2024-10-29 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
AU2016263808B2
(en)
|
2015-05-21 |
2019-01-03 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
AU2016276158B2
(en)
|
2015-06-08 |
2022-06-30 |
Debiopharm International, S.A. |
Anti-CD37 immunoconjugate and anti-CD20 antibody combinations
|
|
JP2018526972A
(ja)
|
2015-06-16 |
2018-09-20 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ３抗体及び使用方法
|
|
TW201718647A
(zh)
|
2015-06-16 |
2017-06-01 |
建南德克公司 |
抗-cll-1抗體及使用方法
|
|
PT3310814T
(pt)
|
2015-06-16 |
2023-10-02 |
H Hoffnabb La Roche Ag |
Anticorpos humanizados e de afinidade amadurecida para fcrh5 e métodos de utilização
|
|
ES2809728T3
(es)
|
2015-06-24 |
2021-03-05 |
Hoffmann La Roche |
Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
|
|
CA2991799A1
(en)
|
2015-07-15 |
2017-01-19 |
Zymeworks Inc. |
Drug-conjugated bi-specific antigen-binding constructs
|
|
CN109476722A
(zh)
|
2015-07-21 |
2019-03-15 |
诺华股份有限公司 |
用于改善免疫细胞的功效和扩张的方法
|
|
PT3317301T
(pt)
|
2015-07-29 |
2021-07-09 |
Novartis Ag |
Terapias de associação compreendendo moléculas de anticorpo contra lag-3
|
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
CN114272371A
(zh)
|
2015-07-29 |
2022-04-05 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
|
US11254744B2
(en)
|
2015-08-07 |
2022-02-22 |
Imaginab, Inc. |
Antigen binding constructs to target molecules
|
|
JP6890581B2
(ja)
|
2015-08-28 |
2021-06-18 |
デビオファーム インターナショナル， エス． アー． |
Ｃｄ３７の検出のための抗体およびアッセイ
|
|
CN108780084B
(zh)
|
2015-09-03 |
2022-07-22 |
诺华股份有限公司 |
预测细胞因子释放综合征的生物标志物
|
|
NZ740616A
(en)
|
2015-09-14 |
2023-05-26 |
Infinity Pharmaceuticals Inc |
Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
|
|
HK1251480A1
(zh)
|
2015-09-21 |
2019-02-01 |
Aptevo Research And Development Llc |
Cd3结合多肽
|
|
DK3356401T3
(da)
|
2015-09-30 |
2020-09-07 |
Igm Biosciences Inc |
Bindingsmolekyler med modificeret j-kæde
|
|
HUE069387T2
(hu)
|
2015-09-30 |
2025-03-28 |
Igm Biosciences Inc |
Módosított J-lánccal rendelkezõ kötõmolekulák
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
US20180282410A1
(en)
|
2015-10-02 |
2018-10-04 |
Hoffmann-La Roche Inc. |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
|
JP6734919B2
(ja)
|
2015-10-02 |
2020-08-05 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
同時結合を測定するための細胞ベースのｆｒｅｔアッセイ法
|
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
|
EP3913000A1
(en)
|
2015-10-02 |
2021-11-24 |
F. Hoffmann-La Roche AG |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
|
AR106201A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
Moléculas biespecíficas de unión a antígeno activadoras de células t
|
|
JP2018536389A
(ja)
|
2015-10-02 |
2018-12-13 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
メソテリンとｃｄ３に結合する二重特異性細胞活性化抗原結合分子
|
|
EP3150637A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Multispecific antibodies
|
|
US20170096495A1
(en)
|
2015-10-02 |
2017-04-06 |
Hoffmann-La Roche Inc. |
Bispecific t cell activating antigen binding molecules
|
|
PL3356411T3
(pl)
|
2015-10-02 |
2021-12-06 |
F. Hoffmann-La Roche Ag |
Przeciwciała dwuswoiste swoiste dla PD1 i TIM3
|
|
CN106565836B
(zh)
*
|
2015-10-10 |
2020-08-18 |
中国科学院广州生物医药与健康研究院 |
高亲和力的可溶性pdl-1分子
|
|
CA3000048A1
(en)
|
2015-10-29 |
2017-05-04 |
F. Hoffmann-La Roche Ag |
Anti-variant fc-region antibodies and methods of use
|
|
HUE057837T2
(hu)
|
2015-11-03 |
2022-06-28 |
Janssen Biotech Inc |
PD-1-et specifikusan kötõ ellenanyagok és alkalmazásaik
|
|
CN108699136B
(zh)
|
2015-12-07 |
2022-03-18 |
Xencor股份有限公司 |
结合cd3和psma的异二聚抗体
|
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
IL313608A
(en)
|
2015-12-09 |
2024-08-01 |
Hoffmann La Roche |
Antibody against CD20 type II to reduce the formation of antibodies against drugs
|
|
CN106883297B
(zh)
|
2015-12-16 |
2019-12-13 |
苏州康宁杰瑞生物科技有限公司 |
基于ch3结构域的异二聚体分子、其制备方法及用途
|
|
EP4424322A3
(en)
|
2015-12-17 |
2025-04-16 |
Novartis AG |
Antibody molecules to pd-1 and uses thereof
|
|
CA3008102A1
(en)
|
2015-12-18 |
2017-06-22 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
|
MA44140A
(fr)
|
2015-12-22 |
2021-05-19 |
Dana Farber Cancer Inst Inc |
Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse
|
|
EP3398965A4
(en)
|
2015-12-28 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR PROMOTING THE EFFICIENCY OF CLEANING POLYPEPTIDE WITH FC REGION
|
|
EP3397755B1
(en)
|
2015-12-28 |
2024-11-06 |
Novartis AG |
Methods of making chimeric antigen receptor -expressing cells
|
|
CN108368179B
(zh)
|
2016-01-08 |
2022-08-23 |
豪夫迈·罗氏有限公司 |
使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法
|
|
CN116334113A
(zh)
*
|
2016-01-08 |
2023-06-27 |
加利福尼亚大学董事会 |
有条件活性的异二聚体多肽及其使用方法
|
|
IL260218B2
(en)
|
2016-01-11 |
2023-04-01 |
Novartis Ag |
Humanized monoclonal antibodies that elicit an immune response against interleukin-2, and their fusion proteins
|
|
JOP20170045B1
(ar)
|
2016-02-19 |
2021-08-17 |
Novartis Ag |
مركبات بيريدون رباعية الحلقة كمضادات فيروسية
|
|
EP3423482A1
(en)
|
2016-03-04 |
2019-01-09 |
Novartis AG |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
US11369660B2
(en)
|
2016-03-08 |
2022-06-28 |
Universitat Zurich |
Method of treating cancer with an HLA-B57 open conformer
|
|
HUE061946T2
(hu)
|
2016-03-22 |
2023-09-28 |
Hoffmann La Roche |
Proteáz-aktivált T-sejt bispecifikus molekulák
|
|
WO2017163186A1
(en)
|
2016-03-24 |
2017-09-28 |
Novartis Ag |
Alkynyl nucleoside analogs as inhibitors of human rhinovirus
|
|
WO2017165681A1
(en)
|
2016-03-24 |
2017-09-28 |
Gensun Biopharma Inc. |
Trispecific inhibitors for cancer treatment
|
|
US11414497B2
(en)
|
2016-04-13 |
2022-08-16 |
Orimabs Ltd. |
Anti-PSMA antibodies and use thereof
|
|
BR112018069890A2
(pt)
|
2016-05-02 |
2019-02-05 |
Hoffmann La Roche |
polipeptídio de fusão que se liga de forma específica a um alvo, polipeptídio de fusão dimérico, ácido nucleico isolado, par de ácidos nucleicos isolados, célula hospedeira, método para produzir um polipeptídio de fusão, imunoconjugado, formulação farmacêutica, polipeptídio de fusão e uso do polipeptídio de fusão
|
|
AR108377A1
(es)
*
|
2016-05-06 |
2018-08-15 |
Medimmune Llc |
Proteínas de unión biespecíficas y sus usos
|
|
CN107365387B
(zh)
|
2016-05-12 |
2022-03-15 |
阿思科力(苏州)生物科技有限公司 |
一种双特异性抗原结合构建体及其制备方法和应用
|
|
US11339225B2
(en)
|
2016-05-12 |
2022-05-24 |
Asclepius (Suzhou) Technology Company Group, Co., Ltd. |
Bispecific antigen-binding construct and preparation method and use thereof
|
|
MX2018014227A
(es)
|
2016-05-20 |
2019-08-22 |
Harpoon Therapeutics Inc |
Proteinas de union de cadena unica de fragmento variable cd3.
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
MX2018014228A
(es)
|
2016-05-20 |
2019-08-12 |
Harpoon Therapeutics Inc |
Proteina de union de albumina sérica de dominio unico.
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
AU2018276419A1
(en)
|
2016-06-02 |
2019-10-17 |
F. Hoffmann-La Roche Ag |
Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer
|
|
ES2820502T3
(es)
|
2016-06-14 |
2021-04-21 |
Novartis Ag |
Forma cristalina de (R)-4-(5-(ciclopropiletilinil)isoxazol-3-il)-N-hidroxi-2-metil-2-(metilsulfonil)butanamida como agente antibacteriano
|
|
EP3468586B1
(en)
|
2016-06-14 |
2024-08-07 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
|
WO2018005226A2
(en)
*
|
2016-06-22 |
2018-01-04 |
Alkermes, Inc. |
Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
|
|
AU2017281797A1
(en)
|
2016-06-24 |
2019-01-24 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
WO2018005706A1
(en)
|
2016-06-28 |
2018-01-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
|
CN109415435B
(zh)
|
2016-07-04 |
2024-01-16 |
豪夫迈·罗氏有限公司 |
新型抗体形式
|
|
US11098077B2
(en)
|
2016-07-05 |
2021-08-24 |
Chinook Therapeutics, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
|
KR102565885B1
(ko)
|
2016-07-20 |
2023-08-09 |
유니버시티 오브 유타 리서치 파운데이션 |
Cd229 car t 세포 및 이의 사용 방법
|
|
AU2017309314B2
(en)
|
2016-08-10 |
2024-08-22 |
Universität Basel |
MHC class Ia open conformers
|
|
CN109641949B
(zh)
|
2016-08-26 |
2023-09-15 |
赛诺菲 |
促进选择性轻链配对的多特异性抗体
|
|
EP3504244A4
(en)
*
|
2016-08-26 |
2020-08-19 |
Agency for Science, Technology and Research |
MACROPHAGE-STIMULATING PROTEIN RECEPTOR ANTIBODIES (OR OF NANTAIS ORIGINAL RON-RECEPTOR) AND THEIR USES
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
TW201811788A
(zh)
|
2016-09-09 |
2018-04-01 |
瑞士商諾華公司 |
作為抗病毒劑之多環吡啶酮化合物
|
|
WO2018057585A1
(en)
|
2016-09-21 |
2018-03-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use
|
|
CN109952112B
(zh)
|
2016-09-21 |
2024-09-06 |
阿帕特夫研究和发展有限公司 |
Cd123结合蛋白和相关的组合物和方法
|
|
JOP20190061A1
(ar)
|
2016-09-28 |
2019-03-26 |
Novartis Ag |
مثبطات بيتا-لاكتاماز
|
|
EP3519437B1
(en)
|
2016-09-30 |
2021-09-08 |
F. Hoffmann-La Roche AG |
Bispecific antibodies against p95her2
|
|
JP6785372B2
(ja)
|
2016-09-30 |
2020-11-18 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
多重特異性分子の機能分析のためのｓｐｒに基づく二重結合アッセイ
|
|
SG10201913823VA
(en)
|
2016-10-07 |
2020-03-30 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
|
MX2019004327A
(es)
|
2016-10-14 |
2019-10-14 |
Xencor Inc |
Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
|
|
CA3038504A1
(en)
*
|
2016-10-14 |
2018-04-19 |
Dana-Farber Cancer Institute, Inc. |
Modular tetrameric bispecific antibody platform
|
|
WO2018073753A1
(en)
|
2016-10-18 |
2018-04-26 |
Novartis Ag |
Fused tetracyclic pyridone compounds as antivirals
|
|
WO2018085468A1
(en)
|
2016-11-01 |
2018-05-11 |
Anaptysbio, Inc. |
Antibodies directed against programmed death- 1 (pd-1)
|
|
WO2018083633A1
(en)
|
2016-11-02 |
2018-05-11 |
Debiopharm International, S.A. |
Methods for improving anti-cd37 immunoconjugate therapy
|
|
WO2018093821A1
(en)
|
2016-11-15 |
2018-05-24 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
|
AU2017363300A1
(en)
|
2016-11-23 |
2019-06-20 |
Harpoon Therapeutics, Inc. |
Prostate specific membrane antigen binding protein
|
|
WO2018098356A1
(en)
*
|
2016-11-23 |
2018-05-31 |
Harpoon Therapeutics, Inc. |
Psma targeting trispecific proteins and methods of use
|
|
RU2019120398A
(ru)
|
2016-12-03 |
2021-01-12 |
Джуно Терапьютикс, Инк. |
Способы определения дозировки cart-клеток
|
|
US10613083B2
(en)
|
2016-12-22 |
2020-04-07 |
Fundamental Solutions Corporation |
Universal biosensor system for analyte detection
|
|
HRP20211642T1
(hr)
|
2016-12-22 |
2022-01-21 |
Amgen Inc. |
Derivati benzizotiazola, izotiazolo[3,4-b]piridina, kinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao inhibitori kras g12c za liječenje raka pluća, gušterače ili kolorektalnog karcinoma
|
|
US10537637B2
(en)
|
2017-01-05 |
2020-01-21 |
Gensun Biopharma Inc. |
Checkpoint regulator antagonists
|
|
FI3565844T3
(fi)
|
2017-01-09 |
2023-05-09 |
Tesaro Inc |
Menetelmiä syövän hoitamiseksi anti-pd-1 -vasta-aineilla
|
|
WO2018140845A2
(en)
*
|
2017-01-27 |
2018-08-02 |
Duke University |
Bi-specific antibodies to cd64 and a disease antigen
|
|
US11266745B2
(en)
|
2017-02-08 |
2022-03-08 |
Imaginab, Inc. |
Extension sequences for diabodies
|
|
CN106832002A
(zh)
*
|
2017-02-16 |
2017-06-13 |
上海科医联创生物科技有限公司 |
一种靶向pd‑1的融合蛋白及其相关应用
|
|
US11535668B2
(en)
|
2017-02-28 |
2022-12-27 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
PE20191360A1
(es)
|
2017-03-10 |
2019-10-01 |
Hoffmann La Roche |
Metodo para producir anticuerpos multiespecificos
|
|
CN110914300A
(zh)
|
2017-04-03 |
2020-03-24 |
安康乐济股份有限公司 |
使用ps靶向抗体与免疫肿瘤学药剂治疗癌症的方法
|
|
EP3606946B1
(en)
|
2017-04-03 |
2022-08-24 |
F. Hoffmann-La Roche AG |
Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
|
|
CN110382525B
(zh)
|
2017-04-03 |
2023-10-20 |
豪夫迈·罗氏有限公司 |
免疫缀合物
|
|
MX2019011769A
(es)
|
2017-04-03 |
2019-11-07 |
Hoffmann La Roche |
Anticuerpos que se unen a steap-1.
|
|
IL268527B2
(en)
|
2017-04-05 |
2024-03-01 |
Hoffmann La Roche |
Bispecific antibodies specifically binding to pd1 and lag3
|
|
KR20190136076A
(ko)
|
2017-04-13 |
2019-12-09 |
에프. 호프만-라 로슈 아게 |
암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
|
|
AR111419A1
(es)
|
2017-04-27 |
2019-07-10 |
Novartis Ag |
Compuestos fusionados de indazol piridona como antivirales
|
|
US20200055948A1
(en)
|
2017-04-28 |
2020-02-20 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
UY37718A
(es)
|
2017-05-05 |
2018-11-30 |
Novartis Ag |
2-quinolinonas triciclicas como agentes antibacteriales
|
|
IL300964A
(en)
|
2017-05-12 |
2023-04-01 |
Harpoon Therapeutics Inc |
mesothelin binding proteins
|
|
KR20200026810A
(ko)
|
2017-05-12 |
2020-03-11 |
하푼 테라퓨틱스, 인크. |
Msln 표적화 삼중 특이적 단백질 및 사용 방법
|
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
|
US10676516B2
(en)
|
2017-05-24 |
2020-06-09 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
US20200181274A1
(en)
|
2017-06-01 |
2020-06-11 |
Novartis Ag |
Bispecific antibodies that bind cd 123 cd3
|
|
WO2018223004A1
(en)
|
2017-06-01 |
2018-12-06 |
Xencor, Inc. |
Bispecific antibodies that bind cd20 and cd3
|
|
CA3065120A1
(en)
|
2017-06-02 |
2018-12-06 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
|
EP3635009A1
(en)
*
|
2017-06-07 |
2020-04-15 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for internalizing enzymes
|
|
ES3000510T3
(en)
|
2017-06-09 |
2025-02-28 |
Providence Health & Services Oregon |
Tumor-infiltrating t-cells for use in the treatment of cancer
|
|
MX2019015155A
(es)
|
2017-06-29 |
2020-08-03 |
Juno Therapeutics Inc |
Modelo de raton para valorar toxicidades asociadas con inmunoterapias.
|
|
EP3645122A1
(en)
|
2017-06-30 |
2020-05-06 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
|
|
AR112603A1
(es)
|
2017-07-10 |
2019-11-20 |
Lilly Co Eli |
Anticuerpos biespecíficos inhibidores de punto de control
|
|
HUE054568T2
(hu)
|
2017-07-14 |
2021-09-28 |
Immatics Biotechnologies Gmbh |
Továbbfejlesztett kettõs specificitású polipeptid molekula
|
|
NZ761636A
(en)
|
2017-07-20 |
2023-07-28 |
Aptevo Res & Development Llc |
Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
|
|
WO2019051291A1
(en)
|
2017-09-08 |
2019-03-14 |
Amgen Inc. |
Inhibitors of kras g12c and methods of using the same
|
|
US11987609B2
(en)
*
|
2017-09-25 |
2024-05-21 |
Dingfu Biotarget Co., Ltd. |
Proteinaceous heterodimer and use thereof
|
|
FI3694529T3
(fi)
|
2017-10-13 |
2024-09-17 |
Harpoon Therapeutics Inc |
Trispesifiset proteiinit ja niiden käyttömenetelmät
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
TW201932142A
(zh)
|
2017-10-20 |
2019-08-16 |
瑞士商赫孚孟拉羅股份公司 |
自單特異性抗體產生多特異性抗體之方法
|
|
CN111566124A
(zh)
|
2017-10-25 |
2020-08-21 |
诺华股份有限公司 |
制备表达嵌合抗原受体的细胞的方法
|
|
CN109721657B
(zh)
*
|
2017-10-27 |
2021-11-02 |
北京比洋生物技术有限公司 |
阻断pd-1/pd-l1信号传导途径且活化t细胞的融合蛋白及其用途
|
|
IL274071B2
(en)
|
2017-10-30 |
2025-10-01 |
Hoffmann La Roche |
Method for generating in vivo multispecific antibodies from monospecific antibodies
|
|
MX2020004243A
(es)
|
2017-11-01 |
2020-09-25 |
Juno Therapeutics Inc |
Receptores de anticuerpos y de antigenos quimericos especificos para el antigeno de maduracion de celulas b.
|
|
US12031975B2
(en)
|
2017-11-01 |
2024-07-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
JP2021500902A
(ja)
|
2017-11-01 |
2021-01-14 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
新規ｔｎｆファミリーリガンド三量体含有抗原結合分子
|
|
EP3703821A2
(en)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Bispecific 2+1 contorsbodies
|
|
EP3704150A1
(en)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
The compbody - a multivalent target binder
|
|
PE20200850A1
(es)
|
2017-11-01 |
2020-08-20 |
Juno Therapeutics Inc |
Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos
|
|
MX2020004196A
(es)
|
2017-11-01 |
2020-11-09 |
Hoffmann La Roche |
Trifab-contorsbody.
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
WO2019094637A1
(en)
|
2017-11-08 |
2019-05-16 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-pd-1 sequences
|
|
CN111315749A
(zh)
|
2017-11-17 |
2020-06-19 |
诺华股份有限公司 |
新颖的二氢异噁唑化合物及其在治疗乙型肝炎中的用途
|
|
EP3716980A1
(en)
|
2017-12-01 |
2020-10-07 |
Juno Therapeutics, Inc. |
Methods for dosing and for modulation of genetically engineered cells
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10174092B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
EP3724225A1
(en)
|
2017-12-15 |
2020-10-21 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
|
EP3731867A4
(en)
|
2017-12-19 |
2022-04-06 |
Surrozen Operating, Inc. |
Anti-lrp5/6 antibodies and methods of use
|
|
EP3728323A4
(en)
|
2017-12-19 |
2022-01-26 |
Surrozen Operating, Inc. |
ANTI-FRIZZLED ANTIBODIES AND METHODS OF USE
|
|
SG11202005732XA
(en)
|
2017-12-19 |
2020-07-29 |
Xencor Inc |
Engineered il-2 fc fusion proteins
|
|
US11773171B2
(en)
|
2017-12-19 |
2023-10-03 |
Surrozen Operating, Inc. |
WNT surrogate molecules and uses thereof
|
|
WO2019123285A1
(en)
|
2017-12-20 |
2019-06-27 |
Novartis Ag |
Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals
|
|
AR114001A1
(es)
|
2017-12-21 |
2020-07-08 |
Hoffmann La Roche |
Anticuerpos que se unen a hla- a2 / wt1
|
|
WO2019122054A1
(en)
|
2017-12-22 |
2019-06-27 |
F. Hoffmann-La Roche Ag |
Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
|
|
WO2019129137A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
|
CN109970856B
(zh)
|
2017-12-27 |
2022-08-23 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
|
US20200385478A1
(en)
*
|
2018-01-05 |
2020-12-10 |
Biograph 55, Inc. |
Compositions and methods for cancer immunotherapy
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
CN111699004A
(zh)
|
2018-02-06 |
2020-09-22 |
豪夫迈·罗氏有限公司 |
眼科疾病的治疗
|
|
MA51793A
(fr)
|
2018-02-08 |
2020-12-16 |
Hoffmann La Roche |
Molécules bispécifiques de liaison à l'antigène et procédés d'utilisation
|
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
JP2021514982A
(ja)
|
2018-02-28 |
2021-06-17 |
ノバルティス アーゲー |
インドール−２−カルボニル化合物及びｂ型肝炎治療のためのそれらの使用
|
|
EP3773911A2
(en)
|
2018-04-04 |
2021-02-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
WO2019204665A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
|
AU2019256529A1
(en)
|
2018-04-18 |
2020-11-26 |
Xencor, Inc. |
TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains
|
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
CA3099118A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
JP7266043B2
(ja)
|
2018-05-04 |
2023-04-27 |
アムジエン・インコーポレーテツド |
ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法
|
|
JP7361720B2
(ja)
|
2018-05-10 |
2023-10-16 |
アムジエン・インコーポレーテツド |
がんの治療のためのｋｒａｓ ｇ１２ｃ阻害剤
|
|
MX2020012217A
(es)
|
2018-05-14 |
2021-03-02 |
Harpoon Therapeutics Inc |
Porción de unión para activación condicional de moléculas de inmunoglobulina.
|
|
WO2019227003A1
(en)
|
2018-05-25 |
2019-11-28 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
EP3801631A1
(en)
|
2018-05-30 |
2021-04-14 |
Debiopharm International SA |
Anti-cd37 immunoconjugate dosing regimens
|
|
PE20210320A1
(es)
|
2018-06-01 |
2021-02-16 |
Novartis Ag |
Moleculas de union contra bcma y usos de las mismas
|
|
EP3802535B1
(en)
|
2018-06-01 |
2022-12-14 |
Amgen, Inc |
Kras g12c inhibitors and methods of using the same
|
|
AU2019276656A1
(en)
|
2018-06-01 |
2021-01-07 |
Novartis Ag |
Dosing of a bispecific antibody that bind CD123 and CD3
|
|
JP7357644B2
(ja)
|
2018-06-11 |
2023-10-06 |
アムジエン・インコーポレーテツド |
がんを処置するためのｋｒａｓ ｇ１２ｃ阻害剤
|
|
AU2019336588B2
(en)
|
2018-06-12 |
2022-07-28 |
Amgen Inc. |
KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
|
|
JP7438988B2
(ja)
|
2018-06-13 |
2024-02-27 |
ノバルティス アーゲー |
Ｂｃｍａキメラ抗原受容体及びその使用
|
|
AU2019286396A1
(en)
|
2018-06-14 |
2020-12-17 |
Bioatla, Inc. |
Multi-specific antibody constructs
|
|
CA3103975A1
(en)
*
|
2018-06-21 |
2019-12-26 |
Shattuck Labs, Inc. |
Heterodimeric proteins and uses thereof
|
|
CA3105000A1
(en)
|
2018-06-26 |
2020-01-02 |
Kyowa Kirin Co., Ltd. |
Antibody binding to cell adhesion molecule 3
|
|
JP7397444B2
(ja)
|
2018-06-26 |
2023-12-13 |
協和キリン株式会社 |
コンドロイチン硫酸プロテオグリカン－５に結合する抗体
|
|
US10647773B2
(en)
|
2018-06-29 |
2020-05-12 |
Gensun Biopharma, Inc. |
Trispecific antagonists
|
|
CA3105448A1
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
ES3042082T3
(en)
|
2018-08-31 |
2025-11-18 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
US20210171909A1
(en)
|
2018-08-31 |
2021-06-10 |
Novartis Ag |
Methods of making chimeric antigen receptor?expressing cells
|
|
MA53495A
(fr)
|
2018-08-31 |
2021-12-08 |
Regeneron Pharma |
Stratégie de dosage permettant d'atténuer le syndrome de libération de cytokines pour des anticorps bispécifiques cd3/c20
|
|
KR102846109B1
(ko)
|
2018-09-07 |
2025-08-18 |
화이자 인코포레이티드 |
항-αvβ8 항체 및 그의 조성물 및 용도
|
|
KR20230170813A
(ko)
|
2018-09-12 |
2023-12-19 |
노파르티스 아게 |
항바이러스 피리도피라진디온 화합물
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
CN113286817B
(zh)
|
2018-09-25 |
2025-01-28 |
哈普恩治疗公司 |
Dll3结合蛋白及使用方法
|
|
US20210347851A1
(en)
|
2018-09-28 |
2021-11-11 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
|
EP3856779A1
(en)
|
2018-09-28 |
2021-08-04 |
Novartis AG |
Cd22 chimeric antigen receptor (car) therapies
|
|
IL305106B2
(en)
|
2018-09-29 |
2025-08-01 |
Novartis Ag |
Process of manufacture of a compound for inhibiting the activity of shp2
|
|
SG11202103192RA
(en)
|
2018-10-03 |
2021-04-29 |
Xencor Inc |
Il-12 heterodimeric fc-fusion proteins
|
|
BR112021007946A2
(pt)
|
2018-10-29 |
2021-08-03 |
F. Hoffmann-La Roche Ag |
formulação de anticorpo
|
|
SG11202104188VA
(en)
|
2018-11-01 |
2021-05-28 |
Juno Therapeutics Inc |
Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
|
|
PE20211058A1
(es)
|
2018-11-01 |
2021-06-07 |
Juno Therapeutics Inc |
Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d)
|
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
|
|
CA3120118A1
(en)
|
2018-11-16 |
2020-05-22 |
Juno Therapeutics, Inc. |
Methods of dosing engineered t cells for the treatment of b cell malignancies
|
|
AU2019384118B2
(en)
|
2018-11-19 |
2025-06-12 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
|
|
DK3886875T3
(da)
|
2018-11-30 |
2024-07-29 |
Juno Therapeutics Inc |
Behandlingsfremgangsmåder under anvendelse af adoptiv celleterapi
|
|
US20220041719A1
(en)
|
2018-12-05 |
2022-02-10 |
Morphosys Ag |
Multispecific antigen-binding molecules
|
|
AU2019403486B2
(en)
|
2018-12-20 |
2025-04-24 |
Amgen Inc. |
KIF18A inhibitors
|
|
ES2997190T3
(en)
|
2018-12-20 |
2025-02-14 |
Amgen Inc |
Heteroaryl amides useful as kif18a inhibitors
|
|
CA3123042A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Kif18a inhibitors
|
|
CA3123227A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
|
CN113195056B
(zh)
|
2018-12-21 |
2024-05-07 |
豪夫迈·罗氏有限公司 |
与cd3结合的抗体
|
|
SG11202106525TA
(en)
|
2018-12-24 |
2021-07-29 |
Sanofi Sa |
Multispecific binding proteins with mutant fab domains
|
|
CN111378045B
(zh)
*
|
2018-12-28 |
2022-08-02 |
长春金赛药业有限责任公司 |
二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物
|
|
US20220073630A1
(en)
|
2018-12-28 |
2022-03-10 |
Hoffmann-La Roche, Inc. |
A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
|
|
US20220089752A1
(en)
*
|
2019-01-14 |
2022-03-24 |
The Regents Of The University Of California |
Compositions and methods for modulating cellular internalization
|
|
AR119683A1
(es)
|
2019-01-29 |
2022-01-05 |
Juno Therapeutics Inc |
Anticuerpos y receptores de antígeno quimérico específicos para receptor huérfano 1 similar a receptor de tirosina quinasa (ror1)
|
|
CN119039441A
(zh)
|
2019-02-21 |
2024-11-29 |
马伦戈治疗公司 |
与nkp30结合的抗体分子及其用途
|
|
EP3927745A1
(en)
*
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
|
|
WO2020172571A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
SG11202109406TA
(en)
|
2019-03-01 |
2021-09-29 |
Xencor Inc |
Heterodimeric antibodies that bind enpp3 and cd3
|
|
CA3130080A1
(en)
|
2019-03-01 |
2020-09-10 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
|
AU2020232616A1
(en)
|
2019-03-01 |
2021-09-09 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
|
EP3947440A1
(en)
|
2019-03-29 |
2022-02-09 |
F. Hoffmann-La Roche AG |
Method for generating avid-binding multispecific antibodies
|
|
JP7249432B2
(ja)
|
2019-03-29 |
2023-03-30 |
エフ． ホフマン－ラ ロシュ アーゲー |
多価分子の機能分析のための、ｓｐｒをベースとする結合アッセイ
|
|
US20220193137A1
(en)
*
|
2019-04-04 |
2022-06-23 |
Umc Utrecht Holding B.V. |
Modified immune receptor constructs
|
|
EP3953455A1
(en)
|
2019-04-12 |
2022-02-16 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
|
KR20220004062A
(ko)
|
2019-04-25 |
2022-01-11 |
에프. 호프만-라 로슈 아게 |
반감기가 연장된 활성화 가능한 치료용 다중특이적 폴리펩티드
|
|
MX2021012871A
(es)
|
2019-04-25 |
2021-11-17 |
Hoffmann La Roche |
Generacion de polipeptidos derivados de anticuerpos mediante intercambio de cadenas polipeptidicas.
|
|
CN113924314B
(zh)
|
2019-04-25 |
2024-10-18 |
豪夫迈·罗氏有限公司 |
通过多肽链交换活化的治疗性多特异性多肽
|
|
JP7273195B2
(ja)
|
2019-05-13 |
2023-05-12 |
エフ． ホフマン－ラ ロシュ アーゲー |
干渉抑制薬物動態イムノアッセイ
|
|
BR112021022682A2
(pt)
|
2019-05-14 |
2022-02-22 |
Provention Bio Inc |
Métodos e composições para prevenir diabetes do tipo 1
|
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
|
US11739146B2
(en)
|
2019-05-20 |
2023-08-29 |
Pandion Operations, Inc. |
MAdCAM targeted immunotolerance
|
|
NZ782284A
(en)
|
2019-05-21 |
2024-11-29 |
Amgen Inc |
Solid state forms
|
|
UY38701A
(es)
|
2019-05-21 |
2020-12-31 |
Novartis Ag |
Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
|
|
CA3137463A1
(en)
*
|
2019-05-29 |
2020-10-03 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
BR112021024820A2
(pt)
*
|
2019-06-10 |
2022-01-25 |
Shandong Boan Biotechnology Co Ltd |
Proteína de fusão bifuncional contra pdl1 e tgfss e uso da mesma
|
|
EP3986928A1
(en)
|
2019-06-19 |
2022-04-27 |
F. Hoffmann-La Roche AG |
Method for the generation of a protein expressing cell by targeted integration using cre mrna
|
|
EP3990646B1
(en)
|
2019-06-26 |
2025-03-05 |
F. Hoffmann-La Roche AG |
Mammalian cell lines with sirt-1 gene knockout
|
|
CN114340735B
(zh)
|
2019-06-28 |
2024-11-12 |
璟尚生物制药公司 |
突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂
|
|
JP2022538139A
(ja)
|
2019-07-02 |
2022-08-31 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
変異体インターロイキン－２及び抗ｃｄ８抗体を含む免疫複合体
|
|
CN110327458B
(zh)
*
|
2019-07-09 |
2022-02-25 |
上海交通大学医学院 |
自分泌vegfb在t细胞代谢与功能以及肿瘤免疫治疗中的应用
|
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
|
EP4004045A1
(en)
|
2019-07-31 |
2022-06-01 |
F. Hoffmann-La Roche AG |
Antibodies binding to gprc5d
|
|
BR112022001460A2
(pt)
|
2019-07-31 |
2022-03-22 |
Hoffmann La Roche |
Moléculas de ligação ao antígeno biespecíficas, um ou mais polinucleotídeos isolados, célula hospedeira, método para produzir uma molécula de ligação ao antígeno biespecífica e para tratar uma doença em um indivíduo, composição farmacêutica, uso da molécula de ligação ao antígeno biespecífica e invenção
|
|
CA3147451A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
|
CN114401953A
(zh)
|
2019-08-02 |
2022-04-26 |
美国安进公司 |
Kif18a抑制剂
|
|
JP7655896B2
(ja)
*
|
2019-08-02 |
2025-04-02 |
康方▲藥▼▲業▼有限公司 |
抗ｃｔｌａ４／抗ｐｄ－１二重特異性抗体及びその使用
|
|
US20220289724A1
(en)
|
2019-08-02 |
2022-09-15 |
Amgen Inc. |
Kif18a inhibitors
|
|
CN114391012B
(zh)
|
2019-08-02 |
2025-10-31 |
美国安进公司 |
作为kif18a抑制剂的吡啶衍生物
|
|
AU2020329191B2
(en)
|
2019-08-12 |
2025-12-04 |
Regeneron Pharmaceuticals, Inc. |
Macrophage stimulating 1 receptor (MST1R) variants and uses thereof
|
|
MX2022001882A
(es)
|
2019-08-12 |
2022-05-30 |
Aptevo Res & Development Llc |
Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
|
|
AU2020356407A1
(en)
*
|
2019-09-25 |
2022-04-07 |
Universität Stuttgart |
Binding modules comprising modified EHD2 domains
|
|
WO2021061898A1
(en)
|
2019-09-26 |
2021-04-01 |
Novartis Ag |
Antiviral pyrazolopyridinone compounds
|
|
CN114616239B
(zh)
*
|
2019-10-17 |
2023-08-11 |
北京门罗生物科技有限公司 |
嵌合抗原受体和其中表达有嵌合抗原受体的t细胞
|
|
EP4048671A1
(en)
|
2019-10-24 |
2022-08-31 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
|
|
KR20250175006A
(ko)
|
2019-11-04 |
2025-12-15 |
레볼루션 메디슨즈, 인크. |
Ras 억제제
|
|
CN114867735A
(zh)
|
2019-11-04 |
2022-08-05 |
锐新医药公司 |
Ras抑制剂
|
|
CA3159559A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
TW202128688A
(zh)
|
2019-11-08 |
2021-08-01 |
美商銳新醫藥公司 |
雙環雜芳基化合物及其用途
|
|
EP4058432A1
(en)
|
2019-11-14 |
2022-09-21 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
|
WO2021097212A1
(en)
|
2019-11-14 |
2021-05-20 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
|
SI4065585T1
(sl)
|
2019-11-25 |
2025-11-28 |
Alkermes, Inc. |
Substituirane makrociklične spojine ter z njimi povezani postopki zdravljenja
|
|
BR112022010069A2
(pt)
*
|
2019-11-25 |
2022-09-06 |
Akeso Biopharma Inc |
Anticorpo biespecífico, molécula de ácido nucleico isolada, vetor, célula hospedeira, conjugado, kit, uso do anticorpo biespecífico e composição farmacêutica
|
|
JP2023503161A
(ja)
|
2019-11-26 |
2023-01-26 |
ノバルティス アーゲー |
Ｃｄ１９及びｃｄ２２キメラ抗原受容体及びその使用
|
|
JP7714545B2
(ja)
|
2019-11-26 |
2025-07-29 |
ノバルティス アーゲー |
キメラ抗原受容体及びその使用
|
|
CN114980976A
(zh)
|
2019-11-27 |
2022-08-30 |
锐新医药公司 |
共价ras抑制剂及其用途
|
|
TWI897903B
(zh)
|
2019-12-13 |
2025-09-21 |
美商建南德克公司 |
抗ly6g6d抗體及其使用方法
|
|
BR112022012010A2
(pt)
|
2019-12-18 |
2022-08-30 |
Hoffmann La Roche |
Anticorpos, ácido nucleico isolado, célula hospedeira, formulação farmacêutica, uso do anticorpo, método de produção de um anticorpo, método de tratamento de um indivíduo que tem câncer e método de tratamento de um indivíduo que tem uma doença inflamatória ou autoimune
|
|
MX2022007635A
(es)
|
2019-12-18 |
2022-07-19 |
Hoffmann La Roche |
Anticuerpos que se unen a hla-a2/mage-a4.
|
|
TWI766512B
(zh)
|
2020-01-02 |
2022-06-01 |
瑞士商赫孚孟拉羅股份公司 |
用於判定腦中的治療性抗體量之方法
|
|
JP2023509708A
(ja)
|
2020-01-03 |
2023-03-09 |
マレンゴ・セラピューティクス，インコーポレーテッド |
抗ｔｃｒ抗体分子およびその使用
|
|
AU2021206217A1
(en)
|
2020-01-07 |
2022-09-01 |
Revolution Medicines, Inc. |
SHP2 inhibitor dosing and methods of treating cancer
|
|
IL294461A
(en)
|
2020-01-13 |
2022-09-01 |
Aptevo Res & Development Llc |
Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
|
|
BR112022013725A2
(pt)
|
2020-01-13 |
2022-10-11 |
Aptevo Res & Development Llc |
Formulações para agentes terapêuticos proteicos
|
|
JP2023511331A
(ja)
*
|
2020-01-16 |
2023-03-17 |
カイロス セラピューティクス， インコーポレイテッド |
骨髄腫細胞および卵巣がん細胞に特異的なヒト化抗体
|
|
WO2021163618A1
(en)
|
2020-02-14 |
2021-08-19 |
Novartis Ag |
Method of predicting response to chimeric antigen receptor therapy
|
|
US11981715B2
(en)
|
2020-02-21 |
2024-05-14 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a CD39 effector
|
|
AU2021224851A1
(en)
|
2020-02-21 |
2022-09-15 |
Harpoon Therapeutics, Inc. |
FLT3 binding proteins and methods of use
|
|
KR20220147109A
(ko)
|
2020-02-27 |
2022-11-02 |
노파르티스 아게 |
키메라 항원 수용체 발현 세포의 제조 방법
|
|
WO2021171264A1
(en)
|
2020-02-28 |
2021-09-02 |
Novartis Ag |
Dosing of a bispecific antibody that binds cd123 and cd3
|
|
WO2021188770A1
(en)
|
2020-03-18 |
2021-09-23 |
Memorial Sloan Kettering Cancer Center |
Anti-ceramide antibodies
|
|
KR20220160023A
(ko)
*
|
2020-03-27 |
2022-12-05 |
바이오테스트 아게 |
조절성 t 세포를 활성화하는 하나 이상의 에피토프를 포함하는 단백질
|
|
KR20230009386A
(ko)
|
2020-04-10 |
2023-01-17 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ｂ-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도
|
|
PH12022552436A1
(en)
|
2020-04-15 |
2024-01-03 |
Hoffmann La Roche |
Immunoconjugates
|
|
EP4142722A1
(en)
|
2020-04-30 |
2023-03-08 |
Bristol-Myers Squibb Company |
Methods of treating cytokine-related adverse events
|
|
JP2023524149A
(ja)
|
2020-05-08 |
2023-06-08 |
ジェンマブ エー／エス |
Ｃｄ３およびｃｄ２０に対する二重特異性抗体
|
|
CA3177288A1
(en)
|
2020-05-11 |
2021-11-18 |
F.Hoffmann-La Roche Ag |
Combination therapy with modified pbmcs and an immunoconjugate
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
US12006366B2
(en)
|
2020-06-11 |
2024-06-11 |
Provention Bio, Inc. |
Methods and compositions for preventing type 1 diabetes
|
|
MX2022016355A
(es)
|
2020-06-18 |
2023-04-03 |
Revolution Medicines Inc |
Metodos para retardar, prevenir, y tratar la resistencia adquirida a inhibidores de ras.
|
|
CN111675763B
(zh)
*
|
2020-06-18 |
2024-02-09 |
美国德州精准药靶有限公司 |
抗met和ron双特异性抗体及其抗体-药物偶联物的制备和应用
|
|
EP4168446A1
(en)
|
2020-06-19 |
2023-04-26 |
F. Hoffmann-La Roche AG |
Antibodies binding to cd3 and folr1
|
|
KR20230025672A
(ko)
|
2020-06-19 |
2023-02-22 |
에프. 호프만-라 로슈 아게 |
Cd3 및 cd19에 결합하는 항체
|
|
AU2021291407A1
(en)
|
2020-06-19 |
2022-09-29 |
F. Hoffmann-La Roche Ag |
Antibodies binding to CD3
|
|
AU2021291405A1
(en)
|
2020-06-19 |
2022-09-29 |
F. Hoffmann-La Roche Ag |
Immune activating Fc domain binding molecules
|
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
|
JP2023532951A
(ja)
|
2020-07-08 |
2023-08-01 |
アストラゼネカ・アクチエボラーグ |
タンパク質発現を改善する方法
|
|
WO2022036495A1
(en)
|
2020-08-17 |
2022-02-24 |
Utc Therapeutics Inc. |
Lymphocytes-antigen presenting cells co-stimulators and uses thereof
|
|
EP4200332A1
(en)
|
2020-08-19 |
2023-06-28 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
|
MX2023002045A
(es)
*
|
2020-08-19 |
2023-05-08 |
Pandion Operations Inc |
Anticuerpos anti-pd-1 multiparatopicos y usos de los mismos.
|
|
WO2022042576A1
(zh)
*
|
2020-08-27 |
2022-03-03 |
盛禾(中国)生物制药有限公司 |
一种多功能融合蛋白及其用途
|
|
KR20230081726A
(ko)
|
2020-09-03 |
2023-06-07 |
레볼루션 메디슨즈, 인크. |
Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도
|
|
AU2021342342A1
(en)
|
2020-09-10 |
2023-04-13 |
Genmab A/S |
Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia
|
|
KR20230066391A
(ko)
|
2020-09-10 |
2023-05-15 |
젠맵 에이/에스 |
여포성 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
|
|
US20230312758A1
(en)
|
2020-09-10 |
2023-10-05 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
|
|
CA3192251A1
(en)
|
2020-09-10 |
2022-03-17 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
CA3192255A1
(en)
|
2020-09-10 |
2022-03-17 |
Brian Elliott |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
IL301298A
(en)
|
2020-09-15 |
2023-05-01 |
Revolution Medicines Inc |
Indole derivatives as RAS inhibitors in cancer therapy
|
|
TW202223092A
(zh)
|
2020-09-24 |
2022-06-16 |
瑞士商赫孚孟拉羅股份公司 |
具有基因剔除的哺乳動物細胞株
|
|
EP4240766A2
(en)
|
2020-11-04 |
2023-09-13 |
Genentech, Inc. |
Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
|
|
AU2021374592A1
(en)
|
2020-11-04 |
2023-06-01 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
JP2023548249A
(ja)
|
2020-11-10 |
2023-11-15 |
上海齊魯制藥研究中心有限公司 |
クローディン１８ａ２及びｃｄ３に対する二重特異性抗体及びその使用
|
|
IL302700A
(en)
|
2020-11-13 |
2023-07-01 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
|
JP2023551907A
(ja)
|
2020-12-01 |
2023-12-13 |
アプティーボ リサーチ アンド デベロップメント エルエルシー |
腫瘍関連抗原及びｃｄ３結合タンパク質、関連する組成物、及び方法
|
|
US20240010754A1
(en)
*
|
2020-12-03 |
2024-01-11 |
Jiangsu Hengrui Medicine Co., Ltd. |
Multispecific antigen binding protein
|
|
CA3204091A1
(en)
|
2020-12-08 |
2022-06-16 |
Infinity Pharmaceuticals, Inc. |
Eganelisib for use in the treatment of pd-l1 negative cancer
|
|
MX2023007133A
(es)
|
2020-12-17 |
2023-06-27 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de estos.
|
|
WO2022129313A1
(en)
|
2020-12-18 |
2022-06-23 |
F. Hoffmann-La Roche Ag |
Precursor proteins and kit for targeted therapy
|
|
US11760747B2
(en)
|
2020-12-21 |
2023-09-19 |
Alkermes, Inc. |
Substituted piperidino compounds and related methods of treatment
|
|
EP4267734A1
(en)
|
2020-12-22 |
2023-11-01 |
F. Hoffmann-La Roche AG |
Oligonucleotides targeting xbp1
|
|
CA3203111A1
(en)
|
2020-12-22 |
2022-06-30 |
Kailiang Wang |
Sos1 inhibitors and uses thereof
|
|
MX2023007846A
(es)
|
2021-01-06 |
2023-07-07 |
Hoffmann La Roche |
Tratamiento conjunto que usa un anticuerpo biespecifico contra pd1-lag3 y un anticuerpo biespecifico de linfocitos t cd20.
|
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
|
AU2022223692A1
(en)
|
2021-02-17 |
2023-09-21 |
Aptevo Research And Development Llc |
Compositions comprising 4-1bb and ox40 binding proteins and methods of use
|
|
CN116888473A
(zh)
|
2021-02-18 |
2023-10-13 |
豪夫迈·罗氏有限公司 |
用于解析复杂、多步骤抗体相互作用的方法
|
|
EP4305067A1
(en)
|
2021-03-09 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
|
|
CA3237992A1
(en)
|
2021-03-31 |
2022-10-06 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Truncated taci polypeptide and fusion protein and use thereof
|
|
AU2021443863A1
(en)
|
2021-04-30 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
|
AU2021443318A1
(en)
|
2021-04-30 |
2023-09-07 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
JP2024516450A
(ja)
|
2021-05-05 |
2024-04-15 |
レボリューション メディシンズ インコーポレイテッド |
共有結合性ｒａｓ阻害剤及びその使用
|
|
CN117616031A
(zh)
|
2021-05-05 |
2024-02-27 |
锐新医药公司 |
用于治疗癌症的ras抑制剂
|
|
JP2024518378A
(ja)
|
2021-05-05 |
2024-05-01 |
イマティクス バイオテクノロジーズ ゲーエムベーハー |
Ｐｒａｍｅに特異的に結合する抗原結合タンパク質
|
|
TW202309052A
(zh)
|
2021-05-05 |
2023-03-01 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
CA3218542A1
(en)
|
2021-05-12 |
2022-11-17 |
Hua Ying |
Antigen binding molecule specifically binding to rankl and ngf, and medical use thereof
|
|
KR20240007171A
(ko)
|
2021-05-14 |
2024-01-16 |
제넨테크, 인크. |
모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법
|
|
AU2022273737A1
(en)
|
2021-05-14 |
2023-11-16 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Antigen-binding molecule
|
|
EP4341291A1
(en)
|
2021-05-21 |
2024-03-27 |
Aptevo Research and Development LLC |
Dosing regimens for protein therapeutics
|
|
TW202307210A
(zh)
|
2021-06-01 |
2023-02-16 |
瑞士商諾華公司 |
Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途
|
|
CA3218590A1
(en)
|
2021-06-07 |
2022-12-15 |
Providence Health & Services - Oregon |
Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
|
|
JP2024523033A
(ja)
|
2021-06-17 |
2024-06-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規の三重特異的結合分子
|
|
CN117500829A
(zh)
|
2021-06-18 |
2024-02-02 |
豪夫迈·罗氏有限公司 |
双特异性抗ccl2抗体
|
|
JP2024525381A
(ja)
|
2021-07-02 |
2024-07-12 |
ジェネンテック， インコーポレイテッド |
がんを治療するための方法及び組成物
|
|
KR20240032959A
(ko)
|
2021-07-14 |
2024-03-12 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
Hgfr 및 egfr에 특이적으로 결합하는 항원-결합 분자, 및 이의 약학적 용도
|
|
CA3219606A1
(en)
|
2021-07-22 |
2023-01-26 |
F. Hoffmann-La Roche Ag |
Heterodimeric fc domain antibodies
|
|
WO2023006809A1
(en)
|
2021-07-27 |
2023-02-02 |
Morphosys Ag |
Combinations of antigen binding molecules
|
|
EP4377351A1
(en)
|
2021-07-28 |
2024-06-05 |
F. Hoffmann-La Roche AG |
Methods and compositions for treating cancer
|
|
CA3231180A1
(en)
|
2021-09-08 |
2023-03-16 |
Redona Therapeutics, Inc. |
Papd5 and/or papd7 inhibiting 4-oxo-1,4-dihydroquinoline-3-carboxylic acid derivatives
|
|
JP2024534531A
(ja)
|
2021-09-23 |
2024-09-20 |
江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 |
抗ｋｌｂ抗体及び使用
|
|
EP4405379A4
(en)
*
|
2021-09-24 |
2025-08-20 |
Synergy Imt Inc |
COMPOSITION OF RECOMBINANT ANTIGEN-BINDING MOLECULES AND METHOD OF MANUFACTURE AND USE THEREOF
|
|
KR20240067099A
(ko)
|
2021-09-30 |
2024-05-16 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
항-il23 항체 융합 단백질 및 용도
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
PE20241627A1
(es)
|
2021-10-14 |
2024-08-07 |
Hoffmann La Roche |
Nuevos inmunoconjugados de interleucina-7
|
|
EP4429706A1
(en)
|
2021-10-14 |
2024-09-18 |
F. Hoffmann-La Roche AG |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|
|
CN118284809A
(zh)
|
2021-11-25 |
2024-07-02 |
豪夫迈·罗氏有限公司 |
少量抗体副产物的定量
|
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
CN115490771A
(zh)
*
|
2021-12-24 |
2022-12-20 |
合肥天港免疫药物有限公司 |
重组抗体及其应用
|
|
US20250115660A1
(en)
|
2022-01-13 |
2025-04-10 |
Astrazeneca Ab |
Methods of improving protein expression
|
|
TW202337902A
(zh)
|
2022-02-07 |
2023-10-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
特異性結合ｐｓｍａ和ｃｄ３的抗原結合分子及其醫藥用途
|
|
WO2023151661A1
(zh)
|
2022-02-11 |
2023-08-17 |
江苏恒瑞医药股份有限公司 |
免疫缀合物及其用途
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
TW202523314A
(zh)
|
2022-02-14 |
2025-06-16 |
美商基利科學股份有限公司 |
抗病毒吡唑并吡啶酮化合物
|
|
EP4490146A1
(en)
|
2022-03-07 |
2025-01-15 |
Amgen Inc. |
A process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile
|
|
JP2025510572A
(ja)
|
2022-03-08 |
2025-04-15 |
レボリューション メディシンズ インコーポレイテッド |
免疫不応性肺癌を治療するための方法
|
|
CA3245807A1
(en)
|
2022-03-14 |
2025-06-13 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Antigen-binding molecule specifically binding to GPRC5D and CD3 and its medical use
|
|
CN119584984A
(zh)
|
2022-03-23 |
2025-03-07 |
豪夫迈·罗氏有限公司 |
抗cd20/抗cd3双特异性抗体与化学疗法的组合治疗
|
|
CA3255366A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions based on bispecific anti-CD20/anti-CD3 antibodies and methods of use
|
|
US11958906B2
(en)
|
2022-04-13 |
2024-04-16 |
Genentech, Inc. |
Pharmaceutical compositions of mosunetuzumab and methods of use
|
|
CN119421890A
(zh)
|
2022-04-19 |
2025-02-11 |
豪夫迈·罗氏有限公司 |
改进的生产细胞
|
|
EP4532526A1
(en)
|
2022-06-03 |
2025-04-09 |
F. Hoffmann-La Roche AG |
Improved production cells
|
|
IL317476A
(en)
|
2022-06-10 |
2025-02-01 |
Revolution Medicines Inc |
Macrocyclic RAS inhibitors
|
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
|
WO2023246885A1
(zh)
|
2022-06-23 |
2023-12-28 |
江苏恒瑞医药股份有限公司 |
特异性结合dll3和cd3的抗原结合分子及其医药用途
|
|
AU2023320568A1
(en)
|
2022-08-05 |
2025-02-06 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for gprc5d and bcma
|
|
TW202430211A
(zh)
|
2022-10-10 |
2024-08-01 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法
|
|
TW202423970A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
|
|
TW202423969A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
|
|
WO2024079069A1
(en)
|
2022-10-12 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Method for classifying cells
|
|
CN120359029A
(zh)
|
2022-10-14 |
2025-07-22 |
黑钻治疗公司 |
使用异喹啉或6-氮杂-喹啉衍生物治疗癌症的方法
|
|
TW202432596A
(zh)
|
2022-11-01 |
2024-08-16 |
大陸商上海齊魯製藥研究中心有限公司 |
針對磷脂醯肌醇蛋白聚醣3的雙特異性抗體及其應用
|
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
|
CN120187748A
(zh)
|
2022-11-15 |
2025-06-20 |
豪夫迈·罗氏有限公司 |
抗原结合分子
|
|
CN120187749A
(zh)
|
2022-11-15 |
2025-06-20 |
豪夫迈·罗氏有限公司 |
具有可活化效应结构域的重组结合蛋白
|
|
EP4628507A1
(en)
|
2022-11-29 |
2025-10-08 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Cldn18.2/4-1bb binding protein and medical use thereof
|
|
EP4633664A2
(en)
|
2022-12-13 |
2025-10-22 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
|
|
CN120584137A
(zh)
|
2023-01-06 |
2025-09-02 |
阿帕特夫研究和发展有限公司 |
双特异性pd-l1和cd40结合分子以及其用途
|
|
CN120548192A
(zh)
|
2023-01-20 |
2025-08-26 |
豪夫迈·罗氏有限公司 |
免疫缀合物
|
|
CN120569410A
(zh)
|
2023-01-25 |
2025-08-29 |
豪夫迈·罗氏有限公司 |
与csf1r和cd3结合的抗体
|
|
WO2024163494A1
(en)
|
2023-01-31 |
2024-08-08 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating non-small cell lung cancer and triple-negative breast cancer
|
|
WO2024163009A1
(en)
|
2023-01-31 |
2024-08-08 |
Genentech, Inc. |
Methods and compositions for treating urothelial bladder cancer
|
|
EP4671282A1
(en)
|
2023-02-21 |
2025-12-31 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
IL-36R BINDING PROTEIN AND ITS MEDICINAL USE
|
|
EP4676519A1
(en)
|
2023-03-06 |
2026-01-14 |
F. Hoffmann-La Roche AG |
Combination therapy of an anti-egfrviii/anti-cd3 antibody and an tumor-targeted 4-1bb agonist
|
|
WO2024188965A1
(en)
|
2023-03-13 |
2024-09-19 |
F. Hoffmann-La Roche Ag |
Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
|
|
CN121263449A
(zh)
|
2023-03-21 |
2026-01-02 |
拜格拉夫55公司 |
Cd19/cd38多特异性抗体
|
|
WO2024206820A1
(en)
*
|
2023-03-30 |
2024-10-03 |
Dna Twopointo, Inc. |
Fc engineering for heterodimeric antibody format
|
|
WO2024206858A1
(en)
|
2023-03-30 |
2024-10-03 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
CN120917044A
(zh)
|
2023-04-03 |
2025-11-07 |
豪夫迈·罗氏有限公司 |
激动性拆分型抗体
|
|
WO2024208777A1
(en)
|
2023-04-03 |
2024-10-10 |
F. Hoffmann-La Roche Ag |
All-in-one agonistic antibodies
|
|
WO2024211663A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
|
AU2024243852A1
(en)
|
2023-04-07 |
2025-11-06 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
AU2024252604A1
(en)
|
2023-04-11 |
2025-10-23 |
BioRay Pharmaceutical Co., Ltd. |
Anti-ror1 antibody and drug conjugate thereof
|
|
WO2024216016A1
(en)
|
2023-04-14 |
2024-10-17 |
Revolution Medicines, Inc. |
Crystalline forms of a ras inhibitor
|
|
US20240352038A1
(en)
|
2023-04-14 |
2024-10-24 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
|
WO2024229406A1
(en)
|
2023-05-04 |
2024-11-07 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
CN121127493A
(zh)
|
2023-05-08 |
2025-12-12 |
豪夫迈·罗氏有限公司 |
靶向干扰素 α 融合蛋白及使用方法
|
|
TW202508630A
(zh)
|
2023-05-15 |
2025-03-01 |
丹麥商珍美寶股份有限公司 |
治療表現ｃｄ２０之ｂ細胞癌症之方法
|
|
TW202509073A
(zh)
|
2023-05-15 |
2025-03-01 |
丹麥商珍美寶股份有限公司 |
高度純化之依可利單抗組成物
|
|
WO2024238537A1
(en)
|
2023-05-16 |
2024-11-21 |
F. Hoffmann-La Roche Ag |
Pd-1 -regulated il-2 immunocytokine and uses thereof
|
|
WO2024263904A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
WO2024263195A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
AR133071A1
(es)
|
2023-06-30 |
2025-08-20 |
Genmab As |
ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ACTIVACIÓN DE FIBROBLASTOS a Y AL RECEPTOR DE MUERTE 4
|
|
WO2025010272A1
(en)
*
|
2023-07-03 |
2025-01-09 |
Neoimmunetech, Inc. |
Heterodimeric fc molecules and uses thereof
|
|
WO2025021838A1
(en)
|
2023-07-26 |
2025-01-30 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
TW202521576A
(zh)
|
2023-07-30 |
2025-06-01 |
美商健生生物科技公司 |
結合至突變型鈣網蛋白之分子及其用途
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025032071A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
|
WO2025032069A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
|
WO2025036892A1
(en)
|
2023-08-14 |
2025-02-20 |
Morphosys Ag |
Cycat halfbody molecules comprising sterically occluding moieties
|
|
WO2025042742A1
(en)
|
2023-08-18 |
2025-02-27 |
Bristol-Myers Squibb Company |
Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
|
|
WO2025059162A1
(en)
|
2023-09-11 |
2025-03-20 |
Dana-Farber Cancer Institute, Inc. |
Car-engager containing il-2 variants to enhance the functionality of car t cells
|
|
TW202530228A
(zh)
|
2023-10-12 |
2025-08-01 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
WO2025082777A1
(en)
|
2023-10-17 |
2025-04-24 |
Morphosys Ag |
Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
|
|
CN117659172A
(zh)
*
|
2023-10-28 |
2024-03-08 |
郑州大学 |
抗PRV gD蛋白单克隆抗体、其制备方法及应用
|
|
WO2025125386A1
(en)
|
2023-12-14 |
2025-06-19 |
F. Hoffmann-La Roche Ag |
Antibodies that bind to folr1 and methods of use
|
|
WO2025137507A1
(en)
|
2023-12-22 |
2025-06-26 |
Regor Pharmaceuticals, Inc. |
Sos1 inhibitors and uses thereof
|
|
WO2025181189A1
(en)
|
2024-03-01 |
2025-09-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
WO2025202147A1
(en)
|
2024-03-27 |
2025-10-02 |
F. Hoffmann-La Roche Ag |
Interleukin-7 immunoconjugates
|
|
WO2025219504A1
(en)
|
2024-04-19 |
2025-10-23 |
F. Hoffmann-La Roche Ag |
Treatment of ophthalmologic diseases
|
|
WO2025237931A1
(en)
|
2024-05-15 |
2025-11-20 |
F. Hoffmann-La Roche Ag |
Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026003224A2
(en)
|
2024-06-26 |
2026-01-02 |
Iomx Therapeutics Ag |
Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|